3Vote!
MarketIntelligenceCenter.com (Free subscription) | yesterday
Quest Diagnostics (NYSE: DGX) closed yesterday at $59.04. So far the stock has hit a 52-week low of $42.36 and 52-week high of $59.57. Quest Diagnostics stock has been showing support around 58.52 and resistance in the 59.36 range. Technical indicators for the stock are Bullish and S&P gives DGX a positive 4 STAR (out of 5) buy rating. DGX appears on the Investors Observer Hedged Dividend Income...
3Vote!
The Dental Implant Blog (Free subscription) | yesterday
Molecular DNA Tests Positioning Dental Professionals at the Forefront of Oral Medicine – Company Planning the Launch of HPV/Oral Cancer DNA Test in 2010 Nashville, TN – November 16, 2009 – OralDNA Labs™ Inc. (www.OralDNA.com), a specialty diagnostics subsidiary of Quest Diagnostics® Incorporated (NYSE: DGX) focused on bringing advanced laboratory testing to the dental [...]...
3Vote!
MarketIntelligenceCenter.com (Free subscription) | 25/11/2009
Quest Diagnostics (NYSE: DGX) closed yesterday at $58.85. So far the stock has hit a 52-week low of $42.36 and 52-week high of $59.57. Quest Diagnostics stock has been showing support around 58.10 and resistance in the 59.46 range. Technical indicators for the stock are Bullish and S&P gives DGX a positive 4 STAR (out of 5) buy rating. DGX appears on the Investors Observer Hedged Dividend Income...
+Vote!
Medical News Today (Free subscription) | 25/11/2009
Rates of infection by the 2009 H1N1 influenza virus may have peaked in late October, but the pandemic flu virus continues to be a potential source of illness in all age groups, including the elderly, according to a new report by Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services.
3Vote!
MarketIntelligenceCenter.com (Free subscription) | 24/11/2009
Quest Diagnostics (NYSE: DGX) closed yesterday at $58.79. So far the stock has hit a 52-week low of $42.36 and 52-week high of $59.57. Quest Diagnostics stock has been showing support around 57.98 and resistance in the 59.24 range. Technical indicators for the stock are Bullish and S&P gives DGX a positive 4 STAR (out of 5) buy rating. DGX appears on the Investors Observer Hedged Dividend Income...
3Vote!
PR News Wire (Free subscription) | 23/11/2009
NORCROSS, Ga., Nov. 23 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced that access to its presentation at the Piper Jaffray 21st Annual Health Care Conference in New York, NY will be available via a live, simultaneous webcast.
3Vote!
MassDevice - Medical device news, information and jobs... (Free subscription) | 21/11/2009
Swine Flu infections may have already peaked, according to analysis of incidence data studied by Quest Diagnostics. In its monthly "Health Trends" report released Nov. 20, researchers at Quest Diagnostics Inc. found that demand for the company's 2009 H1N1 influenza virus test kit started to slide since Oct. 27. Positive test results also began to drop across most age groups and in most regions...
3Vote!
The Earth Times Online Newspaper (Free subscription) | 20/11/2009
MADISON, N.J., Nov. 20 -- Quest Diagnostics Incorporated (the "Company") (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today the final results for its previously announced cash tender offer (the "Te...
3Vote!
PharmaGossip (Free subscription) | 20/11/2009
Justice Department Recovers $2.4 Billion in False Claims Cases in Fiscal Year 2009; More Than $24 Billion Since 1986 FY09 Recovery is Second Largest in History WASHINGTON, Nov. 19 /PRNewswire-USNewswire/ -- The United States secured $2.4 billion in settlements and judgments in cases involving fraud against the government in the fiscal year ending Sept. 30, 2009, the Justice Department announced today....
3Vote!
The Medical Quack (Free subscription) | 20/11/2009
The test has been approved here in the US by emergency declaration a few months ago. Quest recently posted 3rd quarter profits of 1.9 billion so they are doing a lot of tests. I did a short interview with their VP of sales with MedPlus, the IT connection with the company not too long ago and you can read more at the link below. Quest Diagnostics and Health IT – Interview with Rohit Nayak, Vice...
3Vote!
MarketIntelligenceCenter.com (Free subscription) | 19/11/2009
Quest Diagnostics (NYSE: DGX) closed yesterday at $58.48. So far the stock has hit a 52-week low of $40.00 and 52-week high of $59.57. The proprietary Key Risk Ranking for DGX has declined from a 3 KEY Moderate Relative Risk to a 2 KEY Considerable Relative Risk. This Key Ranking is determined daily and is a measure of the relative risk f...
3Vote!
MarketIntelligenceCenter.com (Free subscription) | 19/11/2009
Quest Diagnostics (NYSE: DGX) closed yesterday at $58.48. So far the stock has hit a 52-week low of $40.00 and 52-week high of $59.57. The proprietary Key Risk Ranking for DGX has declined from a 4 KEY Low Relative Risk to a 3 KEY Moderate Relative Risk. This Key Ranking is determined daily and is a measure of the relative risk for a ...
3Vote!
Effect Measure (Free subscription) | 19/11/2009
The Director of Loyola University Medical Center's clinical microbiology laboratory is reported as saying that rapid flu tests are a public health risk. Here's some of what he said and then my explanation as to why it is misleading or just plain wrong: Rapid influenza diagnostic tests used in doctors' offices, hospitals and medical laboratories to detect H1N1 are virtually useless and could pose a...
3Vote!
MassDevice - Medical device news, information and jobs... (Free subscription) | 18/11/2009
The new test uses reverse-transcription polymerase chain reactions found from nasal and throat samples to detect the flu virus. Physicians have lauded its speed, noting that "fast turnaround time(s) can aid in clinical management of patients and allow hospitals to segregate infected patients from other high-risk individuals," according to Dr. Harald Kessler, head of the molecular research...
Videos